Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
AbbVie Inc.
ABBV
$234.00
Name : AbbVie Inc.
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $413,567,975,424.00
EPSttm : 1.31
finviz dynamic chart for ABBV
AbbVie Inc.
$234.00
0.71%
$1.64

Float Short %

1.07

Margin Of Safety %

-5

Put/Call OI Ratio

0.82

EPS Next Q Diff

1.16

EPS Last/This Y

8.24

EPS This/Next Y

3.64

Price

233.97

Target Price

246.74

Analyst Recom

1.81

Performance Q

13.49

Relative Volume

0.89

Beta

0.34

Ticker: ABBV




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-10-20ABBV232.060.770.29330142
2025-10-21ABBV231.410.760.41334464
2025-10-22ABBV228.710.760.74335748
2025-10-23ABBV228.240.770.15336828
2025-10-24ABBV228.030.790.41332118
2025-10-27ABBV228.030.811.83325336
2025-10-28ABBV227.560.830.45331065
2025-10-29ABBV225.260.830.54332198
2025-10-30ABBV228.190.831.03335070
2025-10-31ABBV218.120.861.18352239
2025-11-03ABBV212.20.821.26336323
2025-11-04ABBV215.970.830.44342519
2025-11-05ABBV216.80.820.75346345
2025-11-06ABBV219.090.820.76347595
2025-11-07ABBV219.270.820.50348518
2025-11-10ABBV218.650.820.66334543
2025-11-11ABBV225.250.820.46337373
2025-11-12ABBV233.30.821.05339268
2025-11-13ABBV232.290.830.50350775
2025-11-14ABBV232.420.820.66355523
2025-11-17ABBV233.90.820.58347479
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-10-20ABBV232.06-39.825964.610.71
2025-10-21ABBV231.37-39.825584.310.70
2025-10-22ABBV228.68-39.825345.810.70
2025-10-23ABBV228.23-39.925611.810.55
2025-10-24ABBV228.04-40.025639.810.55
2025-10-27ABBV228.02-40.025668.910.55
2025-10-28ABBV227.54-40.025606.910.55
2025-10-29ABBV225.32-40.025399.210.55
2025-10-30ABBV228.20-40.526034.910.86
2025-10-31ABBV218.08-40.524457.810.86
2025-11-03ABBV212.0454.124920.110.55
2025-11-04ABBV215.8455.626158.810.57
2025-11-05ABBV216.7955.625777.810.57
2025-11-06ABBV219.0555.427301.410.61
2025-11-07ABBV219.1655.327031.110.64
2025-11-10ABBV218.7155.326960.610.64
2025-11-11ABBV225.1755.427785.710.64
2025-11-12ABBV233.2655.427962.910.64
2025-11-13ABBV232.3455.326880.810.63
2025-11-14ABBV232.4055.326997.510.63
2025-11-17ABBV233.9755.427174.610.64
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-10-20ABBV-3.05-0.190.92
2025-10-21ABBV-3.05-0.190.92
2025-10-22ABBV-3.05-0.190.92
2025-10-23ABBV-3.05-0.190.92
2025-10-24ABBV-3.05-0.190.92
2025-10-27ABBV-3.050.111.02
2025-10-28ABBV-3.050.111.02
2025-10-29ABBV-3.050.111.02
2025-10-30ABBV-3.050.111.02
2025-10-31ABBV-3.050.111.02
2025-11-03ABBV-3.050.081.02
2025-11-04ABBV-3.050.081.02
2025-11-05ABBV-3.050.081.02
2025-11-06ABBV-3.050.081.02
2025-11-07ABBV-3.050.081.02
2025-11-10ABBV-3.050.051.02
2025-11-11ABBV-2.370.051.02
2025-11-12ABBV-2.370.051.07
2025-11-13ABBV-2.370.051.07
2025-11-14ABBV-2.370.051.07
2025-11-17ABBV-2.37-0.491.07
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

1.86

Avg. EPS Est. Current Quarter

3.36

Avg. EPS Est. Next Quarter

3.02

Insider Transactions

-2.37

Institutional Transactions

-0.49

Beta

0.34

Average Sales Estimate Current Quarter

16399

Average Sales Estimate Next Quarter

14710

Fair Value

223.16

Quality Score

60

Growth Score

81

Sentiment Score

98

Actual DrawDown %

4.4

Max Drawdown 5-Year %

-21.9

Target Price

246.74

P/E

176.56

Forward P/E

16.37

PEG

10.93

P/S

6.93

P/B

P/Free Cash Flow

21.01

EPS

1.33

Average EPS Est. Cur. Y​

10.64

EPS Next Y. (Est.)

14.28

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

3.94

Relative Volume

0.89

Return on Equity vs Sector %

-115.8

Return on Equity vs Industry %

-125.5

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.07

EBIT Estimation

27174.6
AbbVie Inc.
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 55000
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
stock quote shares ABBV – AbbVie Inc. Stock Price stock today
news today ABBV – AbbVie Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ABBV – AbbVie Inc. yahoo finance google finance
stock history ABBV – AbbVie Inc. invest stock market
stock prices ABBV premarket after hours
ticker ABBV fair value insiders trading